Rznomics Inc. (476830.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩22,550 (-1.10%) as of
Key statistics
- Market cap
- 632.65B
- Dividend yield
- 0.00%
- 52-week range
- 19,990.00 – 122,625.00
- Profit margin
- 0.00%
- Volume
- 219.87k
About Rznomics Inc.
Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is headquartered in Seongnam-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seongnam-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.